28469919|t|Osimertinib administration via nasogastric tube in an EGFR-T790M-positive patient with leptomeningeal metastases.
28469919|a|Patients with an epidermal growth factor receptor (EGFR) mutation are usually administered EGFR-tyrosine kinase inhibitors (TKIs) as standard-of-care treatment. However, acquired resistance occurs between 9 and 13 months. The T790M-resistant mutations are the most common, and osimertinib has been found to be effective in treating EGFR-T790M-positive patients. A 73-year-old female lung cancer patient with an EGFR-sensitizing mutation was receiving fourth-line chemotherapy when she complained of anorexia, headache, and irritability. A lumbar puncture showed adenocarcinoma in the cerebrospinal fluid (CSF), which led to the diagnosis of leptomeningeal metastasis. Her performance status (PS) deteriorated quickly and she also developed dysphagia. The EGFR mutation testing of the CSF demonstrated L858R+T790M double mutations, and an osimertinib suspension was subsequently administered through a nasogastric tube. The PS improved to 1, oral intake became possible after 20 days, and further improvements were observed by gadolinium-enhanced magnetic resonance imaging. The patient remains progression-free for 10 months after osimertinib administration.
28469919	0	11	Osimertinib	Chemical	MESH:C000596361
28469919	54	58	EGFR	Gene	1956
28469919	59	64	T790M	ProteinMutation	tmVar:p|SUB|T|790|M;HGVS:p.T790M;VariantGroup:0;CorrespondingGene:1956;RS#:121434569;CorrespondingSpecies:9606;CA#:90928
28469919	74	81	patient	Species	9606
28469919	102	112	metastases	Disease	MESH:D009362
28469919	114	122	Patients	Species	9606
28469919	131	163	epidermal growth factor receptor	Gene	1956
28469919	165	169	EGFR	Gene	1956
28469919	205	209	EGFR	Gene	1956
28469919	340	345	T790M	ProteinMutation	tmVar:p|SUB|T|790|M;HGVS:p.T790M;VariantGroup:0;CorrespondingGene:1956;RS#:121434569;CorrespondingSpecies:9606;CA#:90928
28469919	391	402	osimertinib	Chemical	MESH:C000596361
28469919	446	450	EGFR	Gene	1956
28469919	451	456	T790M	ProteinMutation	tmVar:p|SUB|T|790|M;HGVS:p.T790M;VariantGroup:0;CorrespondingGene:1956;RS#:121434569;CorrespondingSpecies:9606;CA#:90928
28469919	466	474	patients	Species	9606
28469919	497	508	lung cancer	Disease	MESH:D008175
28469919	509	516	patient	Species	9606
28469919	525	529	EGFR	Gene	1956
28469919	613	621	anorexia	Disease	MESH:D000855
28469919	623	631	headache	Disease	MESH:D006261
28469919	637	649	irritability	Disease	MESH:D001523
28469919	676	690	adenocarcinoma	Disease	MESH:D000230
28469919	755	780	leptomeningeal metastasis	Disease	MESH:D009362
28469919	854	863	dysphagia	Disease	MESH:D003680
28469919	869	873	EGFR	Gene	1956
28469919	915	920	L858R	ProteinMutation	tmVar:p|SUB|L|858|R;HGVS:p.L858R;VariantGroup:1;CorrespondingGene:1956;RS#:121434568;CorrespondingSpecies:9606;CA#:126713
28469919	921	926	T790M	ProteinMutation	tmVar:p|SUB|T|790|M;HGVS:p.T790M;VariantGroup:0;CorrespondingGene:1956;RS#:121434569;CorrespondingSpecies:9606;CA#:90928
28469919	952	963	osimertinib	Chemical	MESH:C000596361
28469919	1140	1150	gadolinium	Chemical	MESH:D005682
28469919	1192	1199	patient	Species	9606
28469919	1245	1256	osimertinib	Chemical	MESH:C000596361
28469919	Association	MESH:D009362	RS#:121434569;HGVS:p.T790M;CorrespondingGene:1956
28469919	Negative_Correlation	MESH:C000596361	MESH:D009362
28469919	Association	MESH:D000855	1956
28469919	Association	MESH:D009362	1956
28469919	Negative_Correlation	MESH:C000596361	RS#:121434569;HGVS:p.T790M;CorrespondingGene:1956
28469919	Association	MESH:D001523	1956
28469919	Association	MESH:D006261	1956
28469919	Negative_Correlation	MESH:C000596361	1956
28469919	Association	MESH:D009362	1956

